Anika Therapeutics (ANIK) Tops Q4 EPS by 45c ;Offers Guidance
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $14.30 -0.83%
Revenue Growth %: +3.5%
Financial Fact:
Licensing, milestone and contract revenue: 6K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +3.5%
Financial Fact:
Licensing, milestone and contract revenue: 6K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q4 EPS of $0.31, $0.45 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $30.6 million versus the consensus estimate of $29.1 million.
GUIDANCE:
Anika Therapeutics sees FY2026 revenue of $114-122.5 million, versus the consensus of $116.4 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AeroVironment restates quarterly financials, citing $89M goodwill error
- Netflix (NFLX) sees notable intra-day weakness
- Cosmos Health unit secures 25M-unit manufacturing orderbook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
